Topoisomerase I poisons-induced autophagy: Cytoprotective, Cytotoxic or Non-protective.

Autophagy Rep

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Massey Cancer Center, 401 College St., Richmond, VA 23298, USA.

Published: December 2022

Topoisomerase I inhibitors represent a widely used class of antineoplastic agents that promote both single-stranded and double-stranded breaks in the DNA of tumor cells, leading to tumor cell death. Topotecan and irinotecan are the clinically relevant derivatives of the parent drug, camptothecin. As is the case with many if not most anticancer agents, irinotecan and topotecan promote autophagy. However, whether the autophagy is cytotoxic, cytoprotective, or non-protective is not clearly defined, and may depend largely upon the genetic background of the tumor cell being investigated. This review explores the available literature regarding the nature of the autophagy induced by these clinically utilized topoisomerase I inhibitors in preclinical tumor models with the goal of determining whether the targeting of autophagy might have potential as a therapeutic strategy to enhance the antitumor response and/or overcome drug resistance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10019749PMC
http://dx.doi.org/10.1080/27694127.2022.2155904DOI Listing

Publication Analysis

Top Keywords

topoisomerase inhibitors
8
tumor cell
8
autophagy
5
topoisomerase poisons-induced
4
poisons-induced autophagy
4
autophagy cytoprotective
4
cytoprotective cytotoxic
4
cytotoxic non-protective
4
non-protective topoisomerase
4
inhibitors represent
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!